The invention relates to a combination, such as a combined preparation or
pharmaceutical composition, respectively, which comprises nateglinide (I)
1
or repaglinide and at least one other antidiabetic compound selected from
the group consisting of thiazolidinedione derivatives (glitazones),
sulfonyl urea derivatives and metformin for simultaneous, separate or
sequential use in the prevention, delay of progression or treatment of
diseases, especially metabolic disorders and in particular type 2
diabetes and diseases and conditions associated with diabetes; to a
composition, respectively, which comprises nateglinide and a
pharmaceutically acceptable carrier and to a process of making such
composition; the use of such combination or composition for the
preparation of a medicament for the prevention, delay of progression or
treatment of metabolic disorders; a method of prevention, delay of
progression or treatment of diseases in warm-blooded animals; the use of
such combination or composition for the cosmetic treatment of a mammal in
order to effect a cosmetically beneficial loss of body weight; and to a
method of improving the bodily appearance of a warm-blooded animal.
